Division of Takeda Pharmaceutical Co. Ltd.
Latest From ViroPharma Inc.
For years, brand industry critics have decried the use of “sham” citizen petitions to delay generic drug approvals. But one person’s “sham” is another person’s First Amendment right to petition the government. A House bill tries to thread that needle.
Scrip looks at some the key clinical and regulatory pharma events that will spark attention during the next three months, according to Biomedtracker's latest quarterly outlook report.
Clinical trials are expected to start next year with an antisense clinical candidate for the rare disease, centronuclear myopathy, developed by French start-up Dynacure as part of its collaboration with US antisense specialist Ionis Pharmaceuticals.
This week’s announcements include the retirement of GlaxoSmithKline’s CFO, new CEOs at Complexa, Synlogic and Horizon Discovery, and other new hires at TP Therapeutics and Motif Bio, and a new board member at DBV Technologies.
- Large Molecule
- Specialty Pharmaceuticals
- Therapeutic Areas
- Lev Pharmaceuticals Inc.
- North America
- Parent & Subsidiaries
- Takeda Pharmaceutical Co. Ltd.
- Senior Management
- Contact Info
Phone: (610) 458-7300
730 Stockton Dr.
Exton, PA 19341
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.